Generate Biomedicines
Generate Biomedicines aims to gain an ability to quickly develop new medicines for various applications based on extensive research on how proteins work. The company has numerous drugs in the pipeline, including several projects in collaboration with Amgen.
NewsHeat chart
- Week
- Month
- Year
- Media news
- Corp news
- Combo news
The data in the chart above is based on data derived from our proprietary XP calculation model and may be changed, adjusted and updated without prior notice
Company Valuation
- Valuation
- Share Price
- Cumulative Funding
The data in the tables and charts is based on data from public sources and although we make every effort to compile the data, it may not coincide with the actual data of the issuer.
*** - To view the data, please log into your account or create a new one.
Company valuation calculator
To calculate, specify one of the parameters
Investors
T. Rowe Price
Amgen
Fidelity Management and Research CompanyNews related to Generate Biomedicines
Generate Biomedicines • 16 Nov 2023Generate:Biomedicines Announces Publication of its Chroma Model ...
SOMERVILLE, Mass., November 15, 2023--Generate:Biomedicines today announced a publication in Nature describing Chroma, a generative AI model that can ...
https://finance.yahoo.com/news/generate-biomedicines-announces-publication-chroma-160000264.htmlGenerate Biomedicines • 14 Oct 2023Generate:Biomedicines Announces Close of $273M Series C Financing to Advance Its Generative AI Pipeline
Our Series C round further propels The Generate Platform to increase significantly the precision, speed, and probability of success of novel therapeutics ...
https://finance.yahoo.com/news/generate-biomedicines-announces-close-273m-100000433.html#:~:text=SOMERVILLE%2C%20Mass.%2C%20September%2014,million%20in%20Series%20C%20financing.